Use of individual PK-guided pazopanib dosing: A feasibility study in patients with advanced solid tumors.

Trial Profile

Use of individual PK-guided pazopanib dosing: A feasibility study in patients with advanced solid tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-001567-24).
    • 09 Nov 2013 Status changed from planning to recruiting as reported by European Clinical Trials Database.
    • 29 Jun 2013 Status changed from not yet recruiting to planning as reported by Netherlands Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top